{"id":51607,"date":"2024-05-03T06:24:34","date_gmt":"2024-05-03T04:24:34","guid":{"rendered":"https:\/\/quimark.com\/?p=51607"},"modified":"2024-08-08T15:24:32","modified_gmt":"2024-08-08T13:24:32","slug":"mychoice","status":"publish","type":"post","link":"https:\/\/quimark.com\/en\/mychoice\/","title":{"rendered":"MyChoice\u00aeCDx PLUS"},"content":{"rendered":"<p>[et_pb_section fb_built=\u201d1\u2033 _builder_version=\u201d4.24.2\u2033 _module_preset=\u201ddefault\u201d background_color=\u201d#002855\u2033 custom_padding=\u201d6px||6px||true|false\u201d global_colors_info=\u201d{}\u201d][et_pb_row _builder_version=\u201d4.27 .0\u2033 _module_preset=\u201ddefault\u201d custom_padding=\u201d15px||9px||false|false\u201d global_colors_info=\u201d{}\u201d][et_pb_column type=\u201d4_4\u2033 _builder_version=\u201d4.24.2\u2033 _module_preset=\u201ddefault\u201d global_colors_info=\u201d {}\u201d][et_pb_text _builder_version=\u201d4.27.0\u2033 _module_preset=\u201ddefault\u201d text_font=\u201d|700|||||||\u201d text_text_color=\u201d#FFFFFF\u201d text_font_size=\u201d46px\u201d text_line_height=\u201d1.2em\u201d header_font=\u201d|700|||||||\u201d header_text_color=\u201d#FFFFFF\u201d header_font_size=\u201d46px\u201d header_line_height=\u201d1.2em\u201d background_enable_color=\u201doff\u201d text_orientation=\u201dcenter\u201d width=\u201d66%\u201d module_alignment=\u201dcenter\u201d custom_padding=\u201d42px||18px||false|false\u201d header_font_tablet =\u201d|700|||||||\u201d header_font_phone=\u201d|700|||||||\u201d header_font_last_edited=\u201don|phone\u201d header_font_size_tablet=\u201d46px\u201d header_font_size_phone=\u201d20px\u201d header_font_size_last_edited=\u201don|phone\u201d global_colors_info=\u201d{}\u201d]<\/p>\n<h1>MyChoice\u00aeCDx PLUS<\/h1>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u201d1\u2033 _builder_version=\u201d4.24.2\u2033 _module_preset=\u201ddefault\u201d custom_padding=\u201d10px||4px|||\u201d global_colors_info=\u201d{}\u201d][et_pb_row column_structure=\u201d1_4,3_4\u2033 _builder_version=\u201d4.24.2\u2033 _module_preset=\u201ddefault\u201d custom_margin=\u201d18px|auto||auto||\u201d global_colors_info=\u201d{}\u201d][et_pb_column type=\u201d1_4\u2033 _builder_version=\u201d4.24.2\u2033 _module_preset=\u201ddefault\u201d global_colors_info=\u201d{}\u201d][et_pb_image src=\u201dhttps:\/\/quimark.com\/wp-content\/ uploads\/2024\/08\/coppia-donne_WEB-1.jpg\u201d title_text=\u201dcoppia donne_WEB\u201d _builder_version=\u201d4.27.0\u2033 _module_preset=\u201ddefault\u201d global_colors_info=\u201d{}\u201d][\/et_pb_image][et_pb_image src=\u201dhttps: \/\/quimark.com\/wp-content\/uploads\/2024\/05\/mychoice.png\u201d title_text=\u201dmychoice\u201d _builder_version=\u201d4.24.3\u2033 _module_preset=\u201ddefault\u201d width=\u201d100%\u201d global_colors_info=\u201d{}\u201d][\/et_pb_image][\/et_pb_column][et_pb_column type=\u201d3_4\u2033 _builder_version=\u201d4.24.2\u2033 _module_preset=\u201ddefault \u201d global_colors_info=\u201d{}\u201d][et_pb_text _builder_version=\u201d4.27.0\u2033 text_font=\u201d|600|||||||\u201d text_text_color=\u201d#c8102e\u201d text_font_size=\u201d22px\u201d text_line_height=\u201d1.2em\u201d custom_margin=\u201d||-1px|||\u201d custom_padding=\u201d||17px|||\u201d global_colors_info=\u201d{}\u201d]<\/p>\n<p>HRD test on tumor tissue<\/p>\n<p>[\/et_pb_text][et_pb_text _builder_version=\u201d4.27.0\u2033 text_font=\u201d||||||||\u201d text_text_color=\u201d#000000\u2033 text_font_size=\u201d17px\u201d text_line_height=\u201d1.8em\u201d ol_line_height=\u201d1.8em\u201d header_3_font=\u201d|700|||||||\u201d header_3_font_size=\u201d23px\u201d header_3_line_height=\u201d1.5em\u201d custom_margin=\u201d-10px|||||\u201d global_colors_info=\u201d{}\u201d]<\/p>\n<p><strong>Determination of homologous recombination deficiency (HRD) in ovarian cancer<\/strong><\/p>\n<p><strong>MyChoice CDx Plus is a genomic test<\/strong> that guides medical decisions in the treatment of ovarian cancer with PARP-inhibitor drugs<strong>.<\/strong><\/p>\n<p>The test is performed in laboratories\u00a0<strong><span style=\"background-color: #ffffff; font-size: 17px;\">Myriad Genetics<\/span><span style=\"background-color: #ffffff; font-size: 17px;\"> USA <\/span><\/strong><span style=\"font-size: 17px;\">on a sample of ovarian tumor tissue.<\/span><\/p>\n<p><span style=\"font-size: 17px;\"><a href=\"https:\/\/quimark.com\/wp-content\/uploads\/2024\/05\/MyChoice-STS-Box_26_05_22_EN_REND3D-1.png\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/quimark.com\/wp-content\/uploads\/2024\/05\/MyChoice-STS-Box_26_05_22_EN_REND3D-1-300x230.png\" width=\"300\" height=\"230\" alt=\"\" class=\"wp-image-51671 alignnone size-medium\" style=\"display: block; margin-left: auto; margin-right: auto;\" \/><\/a><\/span><\/p>\n<p><span style=\"font-size: 17px;\">Mutations are searched for <strong>BRCA1 and BRCA2<\/strong> and the genomic instability score is determined\u00a0 <strong>GIS<\/strong> (Genomic Instability Score), to obtain an integrated and accurate HRD score. (<\/span><span style=\"font-size: 17px;\">1-4).<\/span><\/p>\n<p style=\"text-align: center;\"><strong><span style=\"font-size: 17px;\">HRD = BRCA1\/2+GIS<\/span><\/strong><\/p>\n<p style=\"text-align: center;\">MyChoice CDx Plus promptly identifies patients eligible for drug treatment <strong>PARP inhibitors<\/strong> and is the most validated HRD test in ovarian cancer. (1,5-8)<\/p>\n<p>MyChoice CDx Plus is the only HRD test with<\/p>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><strong>FDA approval<\/strong>,(9)<\/li>\n<li>certification <strong>THERE IS<\/strong>,<\/li>\n<li>recommendation in the main <strong>international guidelines<\/strong> on the treatment(10-12) and<\/li>\n<li><strong>prospective data<\/strong> from phase III studies.(1,5-8)<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>MyChoice CDx Plus is a CE marked device, designed to comply with applicable standards and general safety and performance requirements of the<strong> European Directive 98\/79\/CE<\/strong> (in vitro diagnostic medical devices). The declaration of conformity is issued under the responsibility of Myriad Genetic Laboratories, Inc.<\/p>\n<h3><\/h3>\n<h5><strong>Bibliography<\/strong><\/h5>\n<h5>1. Ray-Coquard, Isabelle, et al. \u201cOlaparib Plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.\u201d New England Journal of Medicine, vol. 381, no. 25, 2019, pp. 2416\u20132428.<br \/>2. Timms, Kirsten M, et al. \u201cComparison of Genomic Instability Test Scores Used for Predicting PARP Activity in Ovarian Cancer.\u201d Journal of Clinical Oncology, vol. 38, no. 15_suppl, 2020, pp. 1586\u20131586.<br \/>3. Watkins, Johnathan A et al. \u201cGenomic Scars As Biomarkers Of Homologous Recombination Deficiency And Drug Response In Breast And Ovarian Cancers\u201d. Breast Cancer Research, vol 16, no. 3, 2014.<br \/>4. The Cancer Genome Atlas Research Network. Nature 2011.<br \/>5. Ray-Coquard, Isabelle, et al. \u201cOlaparib Plus Bevacizuamb First-Line Maintenance in Ovarian Cancer: Final Overall Survival Results from the Paola-1\/ENGOT-OV25 Trial.\u201d Annals of Oncology, vol. 34, no. 8, 2023, pp. 681\u2013692.<br \/>6. Gonz\u00e1lez-Mart\u00edn, Antonio, et al. \u201cNiraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.\u201d New England Journal of Medicine, vol. 381, no. 25, 2019, pp. 2391\u20132402.<br \/>7. Gonz\u00e1lez-Mart\u00edn, Antonio, et al. \u201cProgression-Free Survival and Safety at 3.5 Years of Follow-up: Results from the Randomized Phase 3 Prima\/Engot-OV26\/GOG-3012 Trial of Niraparib Maintenance Treatment in Patients with Newly Diagnosed Ovarian Cancer.\u201d European Journal of Cancer, vol. 189, 2023, p. 112908.<br \/>8. Coleman, Robert L., et al. \u201cVeliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.\u201d New England Journal of Medicine, vol. 381, no. 25, 2019, pp. 2403\u20132415.<br \/>9. Cristescu, Razvan et al. \u201c428 Genomic Instability Metric Concordance Between Oncoscan\u2122, Cytosnp And An FDA-Approved HRD Test\u201d. Translational Research, 2020.<br \/>10. Tew, William P., et al. \u201cPoly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update.\u201d Journal of Clinical Oncology, vol. 40, no. 33, 2022, pp. 3878\u20133881.<br \/>11. Miller, Rowan E. et al. \u201cESMO Recommendations On Predictive Biomarker Testing For Homologous Recombination Deficiency And PARP Inhibitor Benefit In Ovarian Cancer\u201d. Annals Of Oncology, vol 31, no. 12, 2020, pp. 1606-1622.<br \/>12. National Comprehensive Cancer Network. Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer. Version 1.2023.<\/h5>\n<h3><\/h3>\n<p><strong>Knowing your HRD status is critical to determining ovarian cancer treatment options\u00a0<\/strong><\/p>\n<p>A condition of homologous recombination deficiency (<strong>HRD) is present in the 48%<\/strong> about ovarian tumors(1) and is <span style=\"background-color: #ffffff; font-size: 17px;\">Often<\/span><span style=\"background-color: #ffffff; font-size: 17px;\">\u00a0<\/span><span style=\"font-size: 17px;\">\u00a0due to a mutation that is found only in cancer.<\/span><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/quimark.com\/wp-content\/uploads\/2024\/05\/MyChoice-deficit-di-ricombinazione-omologa-HRD_EN.jpg\" width=\"680\" height=\"339\" alt=\"\" class=\"wp-image-51670 alignnone size-full\" \/><\/p>\n<p>However, while some <strong>HRD causes<\/strong> are well established, others remain unknown.(2,3,4)<\/p>\n<p>Determining HRD status for ovarian cancer patients may help provide insight into the extent of benefit from therapy with <strong>PARP inhibitors<\/strong>, which determines optimal outcomes for patients with HRD+.<\/p>\n<p>The <strong>Technical specifications<\/strong> of the MyChoice CDx Plus test are found <span style=\"color: #000000;\"><strong><a href=\"https:\/\/myriad-library.s3.amazonaws.com\/technical-specifications\/myChoice+CDx+Plus+Technical+Specifications.pdf\" target=\"_blank\" rel=\"noopener\" style=\"color: #000000;\">here<\/a><\/strong><\/span>.<\/p>\n<p>The evaluation of LOH, TAI and LST allows the determination of HRD <strong>regardless of the specific cause<\/strong>.(3), while it would be very difficult to examine each individual cause. This is why_<\/p>\n<p>\u25cf HRD resulting from epigenetic events such as BRCA1 promoter methylation would not be detected with a gene sequencing approach.(5,6)<br \/>\u25cf HR gene mutations other than BRCA1 and BRCA2 are rare and it is unclear whether they are linked to HRD.(7,8)<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/quimark.com\/wp-content\/uploads\/2024\/05\/MyChoice-BRCA1-e-BRCA2-mutation_EN.jpg\" width=\"1675\" height=\"931\" alt=\"\" class=\"wp-image-51667 alignnone size-full\" srcset=\"https:\/\/quimark.com\/wp-content\/uploads\/2024\/05\/MyChoice-BRCA1-e-BRCA2-mutation_EN.jpg 1675w, https:\/\/quimark.com\/wp-content\/uploads\/2024\/05\/MyChoice-BRCA1-e-BRCA2-mutation_EN-1280x711.jpg 1280w, https:\/\/quimark.com\/wp-content\/uploads\/2024\/05\/MyChoice-BRCA1-e-BRCA2-mutation_EN-980x545.jpg 980w, https:\/\/quimark.com\/wp-content\/uploads\/2024\/05\/MyChoice-BRCA1-e-BRCA2-mutation_EN-480x267.jpg 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) and (max-width: 1280px) 1280px, (min-width: 1281px) 1675px, 100vw\" \/><\/p>\n<p>Unidentified causes of HRD are not detected.<strong><span style=\"font-size: 17px;\"><\/span><\/strong><\/p>\n<table border=\"1\" style=\"border-collapse: collapse; width: 100%;\">\n<tbody>\n<tr>\n<td style=\"width: 50%;\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/quimark.com\/wp-content\/uploads\/2024\/07\/BRC.jpg\" width=\"499\" height=\"137\" alt=\"\" class=\"wp-image-52362 alignnone size-full\" srcset=\"https:\/\/quimark.com\/wp-content\/uploads\/2024\/07\/BRC.jpg 499w, https:\/\/quimark.com\/wp-content\/uploads\/2024\/07\/BRC-480x132.jpg 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) 499px, 100vw\" \/><\/td>\n<td style=\"width: 50%;\">\n<p><strong>BRCA1\/2<br \/><\/strong><\/p>\n<ul>\n<li>Detection and classification of sequence variants and large rearrangements<\/li>\n<li>Identification of somatic and constitutional variants<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width: 50%;\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/quimark.com\/wp-content\/uploads\/2024\/07\/GIS.jpg\" width=\"499\" height=\"136\" alt=\"\" class=\"wp-image-52363 alignnone size-full\" srcset=\"https:\/\/quimark.com\/wp-content\/uploads\/2024\/07\/GIS.jpg 499w, https:\/\/quimark.com\/wp-content\/uploads\/2024\/07\/GIS-480x131.jpg 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) 499px, 100vw\" \/><\/td>\n<td style=\"width: 50%;\">\n<p><strong>LOH + TAI + LST<br \/><\/strong><span style=\"font-family: inherit; font-size: inherit;\">Combined genome-wide assessment of genomic instability status (Genomic Instability Status):<\/span><\/p>\n<ul>\n<li>loss of heterozygosity (LOH),<\/li>\n<li>telomeric allelic imbalance (TAI)<\/li>\n<li>large-scale state transitions (LST)<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>MyChoiceCDx PLUS determines HRD status in various ways, for more comprehensive results.<\/strong><\/p>\n<p>MyChoice screens ovarian cancer tumors using two methods (BRCA1\/2 mutation and genomic instability) to determine a patient&#039;s HRD status.<\/p>\n<p>&nbsp;<\/p>\n<h3>MyChoice, the benchmark HRD test<\/h3>\n<p><strong>Accurate<\/strong><\/p>\n<p>MyChoice identifies 34% in more HRD tumors than tests using %LOH alone.5<\/p>\n<p><strong>Quick<\/strong><\/p>\n<p>Doctors will receive a MyChoice result within 2-3 weeks of the laboratory receiving the sample.<\/p>\n<p><strong>Operable<\/strong><\/p>\n<p>Easy-to-read MyChoice results with GIS interpretation, BRCA1\/BRCA2 and combined results to make informed treatment decisions<\/p>\n<p><strong>Reliable<\/strong><\/p>\n<p>FDA, PMDA, ASCO, NCCN and ESMO trust MyChoice. (9-12)<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/quimark.com\/wp-content\/uploads\/2024\/05\/mychoice-art-3-300x257.png\" width=\"300\" height=\"257\" alt=\"\" class=\"wp-image-51613 alignnone size-medium\" style=\"display: block; margin-left: auto; margin-right: auto;\" \/><\/p>\n<h3>The most complete and accurate HRD test to make therapeutic decisions in a few days<\/h3>\n<p>MyChoice has been shown to identify 34% in more HRD tumors than other methods that use %LOH alone (5), providing more accurate information to make informed treatment decisions.<br \/>\u25cf 27,000 SNPs allow for a more refined analysis of the genome than %LOH alone, which uses 3,500 SNPs and examines only a portion of the genome.<br \/>\u25cf Technology that analyzes BRCA1\/2 for sequence variants and large rearrangements, thus capturing more 5% than other platforms that do not have this technology.5,13,14<\/p>\n<h3>Full clinical validation<\/h3>\n<p>MyChoice is the only HRD test prospectively validated in three phase III studies for use in the first-line treatment of ovarian cancer.14-18<\/p>\n<p>Robust long-term data confirm that the MyChoice test improves survival in patients with newly diagnosed advanced ovarian cancer receiving first-line treatments.14-18<\/p>\n<p>PAOLA-1 n= 806<br \/>FIRST n= 733<br \/>VELIA n=1.140<\/p>\n<h3>HRD tests are not interchangeable<\/h3>\n<table width=\"717\">\n<tbody>\n<tr>\n<td width=\"179\"><\/td>\n<td width=\"179\"><\/td>\n<td width=\"179\">Other HRD tests<\/td>\n<td width=\"179\">\n<p>MyChoiceCDx<\/p>\n<p>&nbsp;<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td rowspan=\"2\" width=\"179\"><strong>BRCA1 &amp; BRCA2<\/strong><\/td>\n<td width=\"179\">Sequence Variants<\/td>\n<td width=\"179\">Yes<\/td>\n<td width=\"179\">Yes<\/td>\n<\/tr>\n<tr>\n<td width=\"179\">\n<p>Extensive Rearrangements<\/p>\n<p>&nbsp;<\/p>\n<\/td>\n<td width=\"179\">No<\/td>\n<td width=\"179\">Yes<\/td>\n<\/tr>\n<tr>\n<td rowspan=\"3\" width=\"179\"><strong>Genomic Instability Score<\/strong><\/td>\n<td width=\"179\">Loss of heterozygosity (LOH)<\/td>\n<td width=\"179\">Yes<\/td>\n<td width=\"179\">Yes<\/td>\n<\/tr>\n<tr>\n<td width=\"179\">\n<p>Telomeric allelic imbalance (TAI)<\/p>\n<p>&nbsp;<\/p>\n<\/td>\n<td width=\"179\">No<\/td>\n<td width=\"179\">Yes<\/td>\n<\/tr>\n<tr>\n<td width=\"179\">Large-scale state transitions (LST)<\/td>\n<td width=\"179\">No<\/td>\n<td width=\"179\">Yes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3>Trusted around the world<\/h3>\n<p>MyChoice CDx is mentioned in the guidelines and is the only HRD test with Level of Evidence 1A (LoE1A) validated in several phase III studies for the first-line treatment of ovarian cancer with PARP inhibitors.14-18<\/p>\n<h3>Recommended by NCCN(12)<\/h3>\n<p>Somatic testing should prioritize the identification of molecular alterations that allow for effective interventions. This includes assessment of BRCA1\/2 status, loss of heterozygosity (LOH), or homologous recombination deficiency (HRD) in the absence of a germline BRCA mutation.<\/p>\n<h3>Recommended by ASCO(9)<\/h3>\n<p>Myriad MyChoice CDx is included in the American Society of Clinical Oncology (ASCO) recommendations for the use of PARP inhibitors for the treatment and management of certain patients with advanced ovarian cancer.<\/p>\n<h3>Recommended by ESMO(10)<\/h3>\n<p>Validated HRD tests based on genomic scarring can be used to guide treatment with PARP inhibitors.<br \/>ESMO recognizes that MyChoice CDx is the only scar-based HRD test validated in the first-line maintenance setting.<\/p>\n<h3>Clear and understandable reports<\/h3>\n<p>Key elements of the report:<br \/>\u25cf Genomic Instability Score (GIS).<br \/>\u25cf Tumor BRCA1\/BRCA2 mutation (tBRCA1\/2)<br \/>\u25cf Interpretation of any somatic BRCA1 and BRCA2 variants<br \/>\u25cf Overall interpretation of the test most relevant for patient management (if multiple tests are detected) <span style=\"font-size: 17px;\">variants)<\/span><\/p>\n<h3 style=\"background-color: #ffffff;\">Technical Specifications (in English)<\/h3>\n<p style=\"text-align: center;\"><a href=\"https:\/\/quimark.com\/wp-content\/uploads\/2024\/08\/myChoiceCDxPlusTechnicalSpecifications.pdf\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/quimark.com\/wp-content\/uploads\/2024\/08\/myChoiceCDx-PLUS-Tech-Specs-JPG-cornice-233x300.jpg\" width=\"233\" height=\"300\" alt=\"\" class=\"wp-image-52475 alignnone size-medium\" srcset=\"https:\/\/quimark.com\/wp-content\/uploads\/2024\/08\/myChoiceCDx-PLUS-Tech-Specs-JPG-cornice-233x300.jpg 233w, https:\/\/quimark.com\/wp-content\/uploads\/2024\/08\/myChoiceCDx-PLUS-Tech-Specs-JPG-cornice.jpg 236w\" sizes=\"(max-width: 233px) 100vw, 233px\" \/><\/a><\/p>\n<p><span style=\"font-size: 17px;\"><\/span><\/p>\n<p><span style=\"font-size: 17px;\"><\/span><\/p>\n<p><span style=\"font-size: 17px;\"><\/span><\/p>\n<p><span style=\"font-size: 17px;\"><\/span><\/p>\n<h5><strong>Bibliography<\/strong><\/h5>\n<h5>1. Moore, Kathleen N, et al. \u201cNiraparib Monotherapy for Late-Line Treatment of Ovarian Cancer (Quadra): A Multicentre, Open-Label, Single-Arm, Phase 2 Trial.\u201d The Lancet Oncology, vol. 20, no. 5, 2019, pp. 636\u2013648.<br \/>2. Da Cunha Colombo Bonadio, Renata Rodrigues, et al. \u201cHomologous Recombination Deficiency in Ovarian Cancer: A Review of Its Epidemiology and Management.\u201d Clinics, 73(Suppl 1), 2018, p. e450s.<br \/>3. Watkins, Johnathan A et al. \u201cGenomic Scars As Biomarkers Of Homologous Recombination Deficiency And Drug Response In Breast And Ovarian Cancers\u201d. Breast Cancer Research, vol 16, no. 3, 2014.<br \/>4. Konstantinopoulos, Panagiotis A., et al. \u201cHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.\u201d Cancer Discovery, vol. 5, no. 11, 2015, pp. 1137\u20131154.<br \/>5. Timms, Kirsten M, et al. \u201cComparison of Genomic Instability Test Scores Used for Predicting PARP Activity in Ovarian Cancer.\u201d Journal of Clinical Oncology, vol. 38, no. 15_suppl, 2020, pp. 1586\u20131586.<br \/>6. Baldwin, Rae L. et al. \u201cBRCA1 Promoter Region Hypermethylation in Ovarian Carcinoma: A Population-based Study.\u201d Cancer Research, vol. 60, no. 19, 2000, pp. 5329-5333.<br \/>Norquist, Barbara M. et al. \u201cInherited Mutations In Women With Ovarian Carcinoma\u201d. JAMA Oncology, vol 2, no. 4, 2016, p. 482.<br \/>7. The Cancer Genome Atlas Research Network. \u201cIntegrated Genomic Analyzes Of Ovarian Carcinoma\u201d. Nature, vol 474, no. 7353, 2011, pp. 609-615.<br \/>8. Weichert, W et al. \u201c216 An Evaluation Of The Performance Of Molecular Assays To Identify Homologous Recombination Deficiency-Positive Tumors In Ovarian Cancer\u201d. Late Breaking Abstracts, 2021.<br \/>9. Tew, William P., et al. \u201cPoly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update.\u201d Journal of Clinical Oncology, vol. 40, no. 33, 2022, pp. 3878\u20133881.<br \/>10. Miller, Rowan E. et al. \u201cESMO Recommendations On Predictive Biomarker Testing For Homologous Recombination Deficiency And PARP Inhibitor Benefit In Ovarian Cancer\u201d. Annals Of Oncology, vol 31, no. 12, 2020, pp. 1606-1622.<br \/>11. Cristescu, Razvan et al. \u201c428 Genomic Instability Metric Concordance Between Oncoscan\u2122, Cytosnp And An FDA-Approved HRD Test\u201d. Translational Research, 2020.<br \/>12. National Comprehensive Cancer Network. Ovarian Cancer\/Fallopian Tube Cancer\/Primary Peritoneal Cancer. Version 1.2023.<br \/>13. https:\/\/info.foundationmedicine.com\/hubfs\/FMI%20Labels\/FoundationOne_CDx_Label_Technical_Info.pdf<br \/>14. Ray-Coquard, Isabelle, et al. \u201cOlaparib plus Bevacizumab First-Line Maintenance in Ovarian Cancer: Final Overall Survival Results from the Paola-1\/ENGOT-OV25 Trial.\u201d Annals of Oncology, vol. 34, no. 8, 2023, pp. 681\u2013692.<br \/>15. Ray-Coquard, Isabelle, et al. \u201cOlaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.\u201d New England Journal of Medicine, vol. 381, no. 25, 2019, pp. 2416\u20132428.<br \/>16. Gonz\u00e1lez-Mart\u00edn, Antonio, et al. \u201cNiraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.\u201d New England Journal of Medicine, vol. 381, no. 25, 2019, pp. 2391\u20132402.<br \/>17. Gonz\u00e1lez-Mart\u00edn, Antonio, et al. \u201cProgression-Free Survival and Safety at 3.5 Years of Follow-up: Results from the Randomized Phase 3 Prima\/Engot-OV26\/GOG-3012 Trial of Niraparib Maintenance Treatment in Patients with Newly Diagnosed Ovarian Cancer.\u201d European Journal of Cancer, vol. 189, 2023, p. 112908.<br \/>18. Coleman, Robert L., et al. \u201cVeliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.\u201d New England Journal of Medicine, vol. 381, no. 25, 2019, pp. 2403\u20132415.<br \/>19. Denkert, Carsten, et al. \u201cHomologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort.\u201d The Journal of Molecular Diagnostics, vol. 24, no. 12, 2022, pp. 1254-1263.<\/h5>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u201d1\u2033 admin_label=\u201ds\u201d _builder_version=\u201d4.25.2\u2033 background_color=\u201d#002855\u2033 custom_padding=\u201d0px||110px||false |false\u201d box_shadow_style=\u201dpreset7\u2033 box_shadow_horizontal=\u201d0px\u201d box_shadow_vertical=\u201d100px\u201d box_shadow_color=\u201d#ffffff\u201d global_module=\u201d51463\u2033 saved_tabs=\u201dall\u201d global_colors_info=\u201d{}\u201d][et_pb_row column_structure=\u201d1_3,1_3,1_3 \u2033 padding_top_bottom_link_1=\u201dtrue\u201d padding_left_right_link_1=\u201dtrue\u201d _builder_version=\u201d4.27.0\u2033 custom_padding=\u201d0px||0px||true\u201d animation_direction=\u201dbottom\u201d global_colors_info=\u201d{}\u201d][et_pb_column type=\u201d1_3\u2033 _builder_version=\u201d 4.25.2\u2033 background_color=\u201d#c8102e\u201d background_color_gradient_direction=\u201d190deg\u201d background_color_gradient_start=\u201d#3fa2f7\u2033 background_color_gradient_start_position=\u201d85%\u201d background_color_gradient_end=\u201drgba(255,255,255,0)\u201d background_color_gradient_end_position =\u201d0%\u201d custom_padding=\u201d70px|70px|70px|70px\u201d custom_padding_tablet=\u201d|10%||10%||true\u201d custom_padding_phone=\u201d\u201d custom_padding_last_edited=\u201don|tablet\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_text _builder_version=\u201d4.27.0\u2033 _module_preset=\u201ddefault\u201d header_2_font_size_tablet=\u201d\u201d header_2_font_size_phone=\u201d22px\u201d header_2_font_size_last_edited=\u201don|phone\u201d global_colors_info=\u201d{}\u201d]<\/p>\n<h2><span style=\"color: #ffffff;\">For information<\/span><\/h2>\n<p>[\/et_pb_text][et_pb_blurb title=\u201dTelephone\u201d use_icon=\u201don\u201d font_icon=\u201d\ue090||divi||400\u2033 icon_color=\u201d#ffffff\u201d icon_placement=\u201dleft\u201d image_icon_width=\u201d28px\u201d _builder_version=\u201d4.27.0\u2033 header_font =\u201d|600|||||||\u201d header_text_color=\u201d#ffffff\u201d header_font_size=\u201d20px\u201d header_line_height=\u201d1.2em\u201d body_font=\u201d||||||||\u201d body_text_color=\u201d#ffffff\u201d body_font_size=\u201d15px\u201d body_line_height=\u201d1.8em\u201d background_layout=\u201ddark\u201d custom_padding=\u201d15px|||\u201d animation_direction=\u201dleft\u201d animation=\u201doff\u201d header_font_size_tablet=\u201d\u201d header_font_size_phone=\u201d18px\u201d header_font_size_last_edited=\u201don|phone\u201d icon_font_size=\u201d28px\u201d global_colors_info=\u201d{}\u201d]<\/p>\n<p>+39 0239261913<\/p>\n<p>[\/et_pb_blurb][et_pb_blurb title=\u201dEmail\u201d use_icon=\u201don\u201d font_icon=\u201d\ue076||divi||400\u2033 icon_color=\u201d#ffffff\u201d icon_placement=\u201dleft\u201d image_icon_width=\u201d28px\u201d _builder_version=\u201d4.27.0\u2033 header_font =\u201d|600|||||||\u201d header_text_color=\u201d#ffffff\u201d header_font_size=\u201d20px\u201d header_line_height=\u201d1.2em\u201d body_font=\u201d|600|||||||\u201d body_text_color=\u201d#ffffff\u201d body_font_size=\u201d15px\u201d body_line_height=\u201d1.8em\u201d background_layout=\u201ddark\u201d custom_padding=\u201d15px|||\u201d animation_direction=\u201dleft\u201d animation=\u201doff\u201d header_font_size_tablet=\u201d\u201d header_font_size_phone=\u201d18px\u201d header_font_size_last_edited=\u201don|phone\u201d icon_font_size=\u201d28px\u201d global_colors_info=\u201d{}\u201d]<\/p>\n<p>info@quimark.com<\/p>\n<p>[\/et_pb_blurb][\/et_pb_column][et_pb_column type=\u201d1_3\u2033 _builder_version=\u201d4.27.0\u2033 background_color=\u201d#c8102e\u201d background_color_gradient_direction=\u201d190deg\u201d background_color_gradient_start=\u201d#3fa2f7\u2033 background_color_gradient_start_position=\u201d8 5%\u201d background_color_gradient_end=\u201drgba(255,255,255,0 )\u201d background_color_gradient_end_position=\u201d0%\u201d custom_padding=\u201d40px|70px|200px|70px|false|false\u201d custom_padding_tablet=\u201d|10%||10%||true\u201d custom_padding_phone=\u201d||160px||false|true\u201d custom_padding_last_edited=\u201don|phone\u201d global_colors_info=\u201d{}\u201d custom_padding__hover=\u201d|||\u201d][et_pb_text _builder_version=\u201d4.27.0\u2033 _module_preset=\u201ddefault\u201d min_height=\u201d 771px\u201d custom_margin=\u201d||-1085px|||\u201d custom_padding=\u201d0px||56px|0px||\u201d global_colors_info=\u201d{}\u201d]<\/p>\n<p><span style=\"color: #ffffff;\">The content of this website is informative about the Quimark company and its products and services,<br \/><\/span><span style=\"color: #ffffff;\">It is not intended as professional medical or health advice.<\/span><\/p>\n<p>[\/et_pb_text][et_pb_blurb icon_placement=&#8221;left&#8221; image_icon_width=&#8221;28px&#8221; _builder_version=&#8221;4.25.2&#8243; header_font=&#8221;|600|||||||&#8221; header_text_color=&#8221;#ffffff&#8221; header_font_size=&#8221;20px&#8221; header_line_height=&#8221;1.2em&#8221; body_font=&#8221;||||||||&#8221; body_text_color=&#8221;#ffffff&#8221; body_font_size=&#8221;15px&#8221; body_line_height=&#8221;1.8em&#8221; background_layout=&#8221;dark&#8221; custom_margin=&#8221;||-155px|||&#8221; custom_padding=&#8221;15px|||&#8221; animation_direction=&#8221;left&#8221; animation=&#8221;off&#8221; icon_font_size=&#8221;28px&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_blurb][\/et_pb_column][et_pb_column type=&#8221;1_3&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;180px|||&#8221; custom_padding_tablet=&#8221;0px|||&#8221; custom_padding_phone=&#8221;&#8221; custom_padding_last_edited=&#8221;on|desktop&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_contact_form captcha=&#8221;off&#8221; email=&#8221;info@quimark.com&#8221; title=&#8221;Invia un messaggio&#8221; custom_message=&#8221;Nuovo messaggio da Quimark||et_pb_line_break_holder||||et_pb_line_break_holder||Nome: %%Nome%%||et_pb_line_break_holder||Email: %%Email%%||et_pb_line_break_holder||Telefono: %%Telefono%%||et_pb_line_break_holder||Messaggio: %%Messaggio%%||et_pb_line_break_holder||||et_pb_line_break_holder||x Acconsento al trattamento dei miei dati personali come espresso nella privacy policy del sito web.&#8221; submit_button_text=&#8221;Invia Messaggio&#8221; module_id=&#8221;et_pb_contact_form_0&#8243; _builder_version=&#8221;4.27.0&#8243; form_field_background_color=&#8221;#FFFFFF&#8221; form_field_text_color=&#8221;#000000&#8243; title_font=&#8221;|700||on|||||&#8221; title_text_color=&#8221;#ffffff&#8221; title_font_size=&#8221;30px&#8221; title_line_height=&#8221;1.6em&#8221; form_field_font=&#8221;Roboto|300|||||||&#8221; form_field_font_size=&#8221;14px&#8221; form_field_line_height=&#8221;1.6em&#8221; custom_button=&#8221;on&#8221; button_text_size=&#8221;14px&#8221; button_text_color=&#8221;#000000&#8243; button_bg_color=&#8221;#ffffff&#8221; button_border_width=&#8221;12px&#8221; button_border_color=&#8221;#ffffff&#8221; button_border_radius=&#8221;0px&#8221; button_letter_spacing=&#8221;1px&#8221; button_font=&#8221;|600||on|||||&#8221; button_use_icon=&#8221;off&#8221; animation_direction=&#8221;top&#8221; title_font_size_tablet=&#8221;&#8221; title_font_size_phone=&#8221;22px&#8221; title_font_size_last_edited=&#8221;on|phone&#8221; border_width_all=&#8221;1px&#8221; border_color_all=&#8221;#8e8e8e&#8221; form_background_color=&#8221;rgba(0,0,0,0)&#8221; locked=&#8221;off&#8221; global_colors_info=&#8221;{}&#8221; button_text_color__hover=&#8221;#474747&#8243; button_text_color__hover_enabled=&#8221;on&#8221; button_bg_color__hover=&#8221;#bfbfbf&#8221; button_bg_color__hover_enabled=&#8221;on&#8221; button_border_color__hover=&#8221;#bfbfbf&#8221; button_border_color__hover_enabled=&#8221;on&#8221; button_letter_spacing__hover=&#8221;2px&#8221; button_letter_spacing__hover_enabled=&#8221;on&#8221;][et_pb_contact_field field_id=&#8221;Nome&#8221; field_title=&#8221;Nome e Cognome&#8221; fullwidth_field=&#8221;on&#8221; _builder_version=&#8221;4.24.2&#8243; global_colors_info=&#8221;{}&#8221; button_text_size__hover_enabled=&#8221;off&#8221; button_one_text_size__hover_enabled=&#8221;off&#8221; button_two_text_size__hover_enabled=&#8221;off&#8221; button_text_color__hover_enabled=&#8221;off&#8221; button_one_text_color__hover_enabled=&#8221;off&#8221; button_two_text_color__hover_enabled=&#8221;off&#8221; button_border_width__hover_enabled=&#8221;off&#8221; button_one_border_width__hover_enabled=&#8221;off&#8221; button_two_border_width__hover_enabled=&#8221;off&#8221; button_border_color__hover_enabled=&#8221;off&#8221; button_one_border_color__hover_enabled=&#8221;off&#8221; button_two_border_color__hover_enabled=&#8221;off&#8221; button_border_radius__hover_enabled=&#8221;off&#8221; button_one_border_radius__hover_enabled=&#8221;off&#8221; button_two_border_radius__hover_enabled=&#8221;off&#8221; button_letter_spacing__hover_enabled=&#8221;off&#8221; button_one_letter_spacing__hover_enabled=&#8221;off&#8221; button_two_letter_spacing__hover_enabled=&#8221;off&#8221; button_bg_color__hover_enabled=&#8221;off&#8221; button_one_bg_color__hover_enabled=&#8221;off&#8221; button_two_bg_color__hover_enabled=&#8221;off&#8221;][\/et_pb_contact_field][et_pb_contact_field field_id=&#8221;Email&#8221; field_title=&#8221;Indirizzo Email&#8221; field_type=&#8221;email&#8221; fullwidth_field=&#8221;on&#8221; _builder_version=&#8221;4.24.2&#8243; global_colors_info=&#8221;{}&#8221; button_text_size__hover_enabled=&#8221;off&#8221; button_one_text_size__hover_enabled=&#8221;off&#8221; button_two_text_size__hover_enabled=&#8221;off&#8221; button_text_color__hover_enabled=&#8221;off&#8221; button_one_text_color__hover_enabled=&#8221;off&#8221; button_two_text_color__hover_enabled=&#8221;off&#8221; button_border_width__hover_enabled=&#8221;off&#8221; button_one_border_width__hover_enabled=&#8221;off&#8221; button_two_border_width__hover_enabled=&#8221;off&#8221; button_border_color__hover_enabled=&#8221;off&#8221; button_one_border_color__hover_enabled=&#8221;off&#8221; button_two_border_color__hover_enabled=&#8221;off&#8221; button_border_radius__hover_enabled=&#8221;off&#8221; button_one_border_radius__hover_enabled=&#8221;off&#8221; button_two_border_radius__hover_enabled=&#8221;off&#8221; button_letter_spacing__hover_enabled=&#8221;off&#8221; button_one_letter_spacing__hover_enabled=&#8221;off&#8221; button_two_letter_spacing__hover_enabled=&#8221;off&#8221; button_bg_color__hover_enabled=&#8221;off&#8221; button_one_bg_color__hover_enabled=&#8221;off&#8221; button_two_bg_color__hover_enabled=&#8221;off&#8221;][\/et_pb_contact_field][et_pb_contact_field field_id=&#8221;Telefono&#8221; field_title=&#8221;Telefono&#8221; fullwidth_field=&#8221;on&#8221; _builder_version=&#8221;4.24.2&#8243; global_colors_info=&#8221;{}&#8221; button_text_size__hover_enabled=&#8221;off&#8221; button_one_text_size__hover_enabled=&#8221;off&#8221; button_two_text_size__hover_enabled=&#8221;off&#8221; button_text_color__hover_enabled=&#8221;off&#8221; button_one_text_color__hover_enabled=&#8221;off&#8221; button_two_text_color__hover_enabled=&#8221;off&#8221; button_border_width__hover_enabled=&#8221;off&#8221; button_one_border_width__hover_enabled=&#8221;off&#8221; button_two_border_width__hover_enabled=&#8221;off&#8221; button_border_color__hover_enabled=&#8221;off&#8221; button_one_border_color__hover_enabled=&#8221;off&#8221; button_two_border_color__hover_enabled=&#8221;off&#8221; button_border_radius__hover_enabled=&#8221;off&#8221; button_one_border_radius__hover_enabled=&#8221;off&#8221; button_two_border_radius__hover_enabled=&#8221;off&#8221; button_letter_spacing__hover_enabled=&#8221;off&#8221; button_one_letter_spacing__hover_enabled=&#8221;off&#8221; button_two_letter_spacing__hover_enabled=&#8221;off&#8221; button_bg_color__hover_enabled=&#8221;off&#8221; button_one_bg_color__hover_enabled=&#8221;off&#8221; button_two_bg_color__hover_enabled=&#8221;off&#8221;][\/et_pb_contact_field][et_pb_contact_field field_id=&#8221;Messaggio&#8221; field_title=&#8221;Messaggio&#8221; field_type=&#8221;text&#8221; fullwidth_field=&#8221;on&#8221; _builder_version=&#8221;4.25.1&#8243; global_colors_info=&#8221;{}&#8221; button_text_size__hover_enabled=&#8221;off&#8221; button_one_text_size__hover_enabled=&#8221;off&#8221; button_two_text_size__hover_enabled=&#8221;off&#8221; button_text_color__hover_enabled=&#8221;off&#8221; button_one_text_color__hover_enabled=&#8221;off&#8221; button_two_text_color__hover_enabled=&#8221;off&#8221; button_border_width__hover_enabled=&#8221;off&#8221; button_one_border_width__hover_enabled=&#8221;off&#8221; button_two_border_width__hover_enabled=&#8221;off&#8221; button_border_color__hover_enabled=&#8221;off&#8221; button_one_border_color__hover_enabled=&#8221;off&#8221; button_two_border_color__hover_enabled=&#8221;off&#8221; button_border_radius__hover_enabled=&#8221;off&#8221; button_one_border_radius__hover_enabled=&#8221;off&#8221; button_two_border_radius__hover_enabled=&#8221;off&#8221; button_letter_spacing__hover_enabled=&#8221;off&#8221; button_one_letter_spacing__hover_enabled=&#8221;off&#8221; button_two_letter_spacing__hover_enabled=&#8221;off&#8221; button_bg_color__hover_enabled=&#8221;off&#8221; button_one_bg_color__hover_enabled=&#8221;off&#8221; button_two_bg_color__hover_enabled=&#8221;off&#8221;][\/et_pb_contact_field][et_pb_contact_field field_id=&#8221;Privacy&#8221; field_title=&#8221;Trattamento dei dati&#8221; field_type=&#8221;checkbox&#8221; checkbox_options=&#8221;%91{%22value%22:%22Acconsento al trattamento dei miei dati personali come espresso nella %22,%22checked%22:0,%22dragID%22:-1,%22link_url%22:%22https:\/\/quimark.com\/privacy-policy\/%22,%22link_text%22:%22privacy policy%22}%93&#8243; fullwidth_field=&#8221;on&#8221; _builder_version=&#8221;4.25.2&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"<p>MyChoice\u00aeCDx PLUSHRD test on tumor tissueDetermination of homologous recombination deficiency (HRD) in ovarian cancer MyChoice CDx Plus is a genomic test that guides medical decisions in the treatment of ovarian cancer with PARP-inhibitors. The test is performed in the Myriad Genetics USA laboratories on a sample of ovarian tumor tissue. The search for [\u2026]<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[13],"tags":[],"class_list":["post-51607","post","type-post","status-publish","format-standard","hentry","category-prodotti"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MyChoice\u00aeCDx PLUS - eurobiodid - Oncologia<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/quimark.com\/en\/mychoice\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MyChoice\u00aeCDx PLUS - eurobiodid - Oncologia\" \/>\n<meta property=\"og:description\" content=\"MyChoice\u00aeCDx PLUSTest HRD su tessuto tumoraleDeterminazione del deficit di ricombinazione omologa (HRD) nel tumore ovarico MyChoice CDx Plus \u00e8 un test genomico che guida le decisioni mediche nel trattamento del tumore ovarico con farmaci PARP-inibitori. Il test \u00e8 eseguito nei laboratori\u00a0Myriad Genetics USA su un campione di tessuto tumorale ovarico. Viene effettuata la ricerca delle [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/quimark.com\/en\/mychoice\/\" \/>\n<meta property=\"og:site_name\" content=\"eurobiodid - Oncologia\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-03T04:24:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-08T13:24:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/quimark.com\/wp-content\/uploads\/2024\/05\/MyChoice-STS-Box_26_05_22_EN_REND3D-1-300x230.png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/quimark.com\/mychoice\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/quimark.com\/mychoice\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/quimark.com\/#\/schema\/person\/5aa5dc5d0d7f1d025ac249d66aa16810\"},\"headline\":\"MyChoice\u00aeCDx PLUS\",\"datePublished\":\"2024-05-03T04:24:34+00:00\",\"dateModified\":\"2024-08-08T13:24:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/quimark.com\/mychoice\/\"},\"wordCount\":3564,\"publisher\":{\"@id\":\"https:\/\/quimark.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/quimark.com\/mychoice\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/quimark.com\/wp-content\/uploads\/2024\/05\/MyChoice-STS-Box_26_05_22_EN_REND3D-1-300x230.png\",\"articleSection\":[\"Prodotti\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/quimark.com\/mychoice\/\",\"url\":\"https:\/\/quimark.com\/mychoice\/\",\"name\":\"MyChoice\u00aeCDx PLUS - eurobiodid - Oncologia\",\"isPartOf\":{\"@id\":\"https:\/\/quimark.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/quimark.com\/mychoice\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/quimark.com\/mychoice\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/quimark.com\/wp-content\/uploads\/2024\/05\/MyChoice-STS-Box_26_05_22_EN_REND3D-1-300x230.png\",\"datePublished\":\"2024-05-03T04:24:34+00:00\",\"dateModified\":\"2024-08-08T13:24:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/quimark.com\/mychoice\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/quimark.com\/mychoice\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/quimark.com\/mychoice\/#primaryimage\",\"url\":\"https:\/\/quimark.com\/wp-content\/uploads\/2024\/05\/MyChoice-STS-Box_26_05_22_EN_REND3D-1-300x230.png\",\"contentUrl\":\"https:\/\/quimark.com\/wp-content\/uploads\/2024\/05\/MyChoice-STS-Box_26_05_22_EN_REND3D-1-300x230.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/quimark.com\/mychoice\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/quimark.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MyChoice\u00aeCDx PLUS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/quimark.com\/#website\",\"url\":\"https:\/\/quimark.com\/\",\"name\":\"eurobiodid - Oncologia\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/quimark.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/quimark.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/quimark.com\/#organization\",\"name\":\"eurobiodid - Oncologia\",\"url\":\"https:\/\/quimark.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/quimark.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/quimark.com\/wp-content\/uploads\/2026\/02\/Eurobio-DID_2220.png\",\"contentUrl\":\"https:\/\/quimark.com\/wp-content\/uploads\/2026\/02\/Eurobio-DID_2220.png\",\"width\":2942,\"height\":759,\"caption\":\"eurobiodid - Oncologia\"},\"image\":{\"@id\":\"https:\/\/quimark.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/quimark.com\/#\/schema\/person\/5aa5dc5d0d7f1d025ac249d66aa16810\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/quimark.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7d166e34bad3546ae92ca13194b06676?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7d166e34bad3546ae92ca13194b06676?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\/\/quimark.com\/en\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MyChoice\u00aeCDx PLUS - eurobiodid - Oncologia","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/quimark.com\/en\/mychoice\/","og_locale":"en_GB","og_type":"article","og_title":"MyChoice\u00aeCDx PLUS - eurobiodid - Oncologia","og_description":"MyChoice\u00aeCDx PLUSTest HRD su tessuto tumoraleDeterminazione del deficit di ricombinazione omologa (HRD) nel tumore ovarico MyChoice CDx Plus \u00e8 un test genomico che guida le decisioni mediche nel trattamento del tumore ovarico con farmaci PARP-inibitori. Il test \u00e8 eseguito nei laboratori\u00a0Myriad Genetics USA su un campione di tessuto tumorale ovarico. Viene effettuata la ricerca delle [&hellip;]","og_url":"https:\/\/quimark.com\/en\/mychoice\/","og_site_name":"eurobiodid - Oncologia","article_published_time":"2024-05-03T04:24:34+00:00","article_modified_time":"2024-08-08T13:24:32+00:00","og_image":[{"url":"https:\/\/quimark.com\/wp-content\/uploads\/2024\/05\/MyChoice-STS-Box_26_05_22_EN_REND3D-1-300x230.png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/quimark.com\/mychoice\/#article","isPartOf":{"@id":"https:\/\/quimark.com\/mychoice\/"},"author":{"name":"admin","@id":"https:\/\/quimark.com\/#\/schema\/person\/5aa5dc5d0d7f1d025ac249d66aa16810"},"headline":"MyChoice\u00aeCDx PLUS","datePublished":"2024-05-03T04:24:34+00:00","dateModified":"2024-08-08T13:24:32+00:00","mainEntityOfPage":{"@id":"https:\/\/quimark.com\/mychoice\/"},"wordCount":3564,"publisher":{"@id":"https:\/\/quimark.com\/#organization"},"image":{"@id":"https:\/\/quimark.com\/mychoice\/#primaryimage"},"thumbnailUrl":"https:\/\/quimark.com\/wp-content\/uploads\/2024\/05\/MyChoice-STS-Box_26_05_22_EN_REND3D-1-300x230.png","articleSection":["Prodotti"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/quimark.com\/mychoice\/","url":"https:\/\/quimark.com\/mychoice\/","name":"MyChoice\u00aeCDx PLUS - eurobiodid - Oncologia","isPartOf":{"@id":"https:\/\/quimark.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/quimark.com\/mychoice\/#primaryimage"},"image":{"@id":"https:\/\/quimark.com\/mychoice\/#primaryimage"},"thumbnailUrl":"https:\/\/quimark.com\/wp-content\/uploads\/2024\/05\/MyChoice-STS-Box_26_05_22_EN_REND3D-1-300x230.png","datePublished":"2024-05-03T04:24:34+00:00","dateModified":"2024-08-08T13:24:32+00:00","breadcrumb":{"@id":"https:\/\/quimark.com\/mychoice\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/quimark.com\/mychoice\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/quimark.com\/mychoice\/#primaryimage","url":"https:\/\/quimark.com\/wp-content\/uploads\/2024\/05\/MyChoice-STS-Box_26_05_22_EN_REND3D-1-300x230.png","contentUrl":"https:\/\/quimark.com\/wp-content\/uploads\/2024\/05\/MyChoice-STS-Box_26_05_22_EN_REND3D-1-300x230.png"},{"@type":"BreadcrumbList","@id":"https:\/\/quimark.com\/mychoice\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/quimark.com\/"},{"@type":"ListItem","position":2,"name":"MyChoice\u00aeCDx PLUS"}]},{"@type":"WebSite","@id":"https:\/\/quimark.com\/#website","url":"https:\/\/quimark.com\/","name":"eurobiodid - Oncologia","description":"","publisher":{"@id":"https:\/\/quimark.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/quimark.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/quimark.com\/#organization","name":"eurobiodid - Oncologia","url":"https:\/\/quimark.com\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/quimark.com\/#\/schema\/logo\/image\/","url":"https:\/\/quimark.com\/wp-content\/uploads\/2026\/02\/Eurobio-DID_2220.png","contentUrl":"https:\/\/quimark.com\/wp-content\/uploads\/2026\/02\/Eurobio-DID_2220.png","width":2942,"height":759,"caption":"eurobiodid - Oncologia"},"image":{"@id":"https:\/\/quimark.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/quimark.com\/#\/schema\/person\/5aa5dc5d0d7f1d025ac249d66aa16810","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/quimark.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7d166e34bad3546ae92ca13194b06676?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7d166e34bad3546ae92ca13194b06676?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/quimark.com\/en\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/quimark.com\/en\/wp-json\/wp\/v2\/posts\/51607"}],"collection":[{"href":"https:\/\/quimark.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/quimark.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/quimark.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/quimark.com\/en\/wp-json\/wp\/v2\/comments?post=51607"}],"version-history":[{"count":65,"href":"https:\/\/quimark.com\/en\/wp-json\/wp\/v2\/posts\/51607\/revisions"}],"predecessor-version":[{"id":52560,"href":"https:\/\/quimark.com\/en\/wp-json\/wp\/v2\/posts\/51607\/revisions\/52560"}],"wp:attachment":[{"href":"https:\/\/quimark.com\/en\/wp-json\/wp\/v2\/media?parent=51607"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/quimark.com\/en\/wp-json\/wp\/v2\/categories?post=51607"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/quimark.com\/en\/wp-json\/wp\/v2\/tags?post=51607"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}